세계의 피하 피임 임플란트 시장 - 규모, 점유율, 동향 분석 보고서 : 제품별, 유통 채널별, 지역별 부문 예측(2025-2030년)

Subdermal Contraceptive Implants Market Size, Share & Trends Analysis Report By Product (Etonogestrel Implant, Levonorgestrel Implant), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,515,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,946,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,809,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 피하 피임 임플란트 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 피하 피임 임플란트 시장 규모는 2030년까지 17억 4,000만 달러에 이를 것으로 추정되며, 2025-2030년까지 CAGR 7.61%로 성장할 전망입니다.

시장에서 다수의 최신 피임약의 도입, 다양한 피임 방법에 대한 의식 증가, 1인당 소득의 상승이 피임용 피하 임플란트 시장을 견인하는 주요 요인의 일부입니다.

Guttmacher Institute에 따르면 2014년에는 약 2,000만 명의 여성이 공적 자금으로 피임 서비스를 필요로 했습니다. CDC에 따르면 2017년 미국에서는 약 4,690만 명의 여성이 적어도 하나의 피임법을 사용했습니다. 피하 임플란트는 여성에게 장기적인 피임 옵션입니다. 피임을 위한 피하 임플란트는 중합체 캡슐 또는 막대의 형태로 피하에 삽입됩니다. 황체 호르몬은 천천히 안정된 속도로 방출되어 1-5년간 유효한 피임 효과를 얻을 수 있습니다.

공적 자금으로 가족 계획 서비스는 여성이 임신을 피하거나 계획적으로 임신하는 데 도움이 됩니다. 2012년 사우스캐롤라이나주 보건복지부(SCDHHS)는 산후 곧 장시간 작용형 가역적 피임약(LARC) 삽입에 대한 메디케이드 결제 방침을 개정했습니다. 이 새로운 결제 정책에 따라 의료 제공업체는 진단 관련 그룹(DRG) 외에 가족 계획 규정자가 있는 J 코드를 사용하여 삽입 절차와 IUD 또는 임플란트 비용을 청구할 수 있습니다.

임플란트는 사하라 이남의 아프리카 여성에게 가장 널리 사용되는 피임법입니다. 이는 제조업체, 기증자, 정부 및 국제기구 간의 관민 파트너십 덕분에 제품 비용을 낮추고 제품 가용성을 높이는 데 도움이 됩니다. 남아프리카, 말라위, 르완다에서는 피임구 사용량이 증가하고 있습니다. PLOS.org에 따르면 말라위에서는 2016년 장기간 작용형 가역적 피임법(LARC) 사용률이 도시 지역에서 10.21%, 농촌 지역에서 9.66%에 달했습니다. 2012년에는 2020년까지 1억 2,000만 명의 여성이 현대 피임법을 이용할 수 있도록 하기 위해 '가족계획 2020(FP2020)'이라는 활동이 시작되었습니다.

피하 피임 임플란트 시장 보고서 하이라이트

• 에토노게스트렐 임플란트가 시장을 독점해 2024년에는 64.73%의 점유율을 차지했습니다. 촉진요인은 의도하지 않은 임신과 안전하지 않은 낙태 증가가 있습니다.
• 병원이 시장을 독점해 2024년에는 54.37%의 점유율을 차지했습니다. 병원은 환자에게 종합적인 환경을 제공하고, 검사, 진찰, 처치 등 폭넓은 서비스를 제공하고 있으며, 이것이 부문 성장의 원동력이 되고 있습니다.
• 북미의 피하 피임 임플란트 시장은 2024년에 64.91%의 점유율을 차지해 시장을 독점했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 피하 피임 임플란트 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 산업의 과제와 기회의 분석
• 피하 피임 임플란트 시장 분석 도구
  • Porter's Five Forces 분석
  • PESTEL 분석

제4장 피하 피임 임플란트 시장 : 제품별, 추정 및 동향 분석

• 정의와 범위
• 제품 시장 점유율 분석, 2024년과 2030년
• 부문 대시보드
• 피하 피임 임플란트 시장 : 제품별, 2018-2030년
  • 에토노게스트렐 임플란트
  • 레보노게스트렐 임플란트

제5장 피하 피임 임플란트 시장 : 유통 채널별, 추정 및 동향 분석

• 정의와 범위
• 유통 채널 시장 점유율 분석, 2024년과 2030년
• 부문 대시보드
• 피하 피임 임플란트 시장 : 유통 채널별, 2018-2030년
  • 병원
  • 부인과 클리닉
  • 커뮤니티 의료 센터
  • 기타

제6장 피하 피임 임플란트 시장 : 지역별, 추정 및 동향 분석

• 정의와 범위
• 지역별 시장 점유율 분석, 2024년과 2030년
• 피하 피임 임플란트 시장 점유율, 지역별, 2024년과 2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업 분류
• 기업의 시장 점유율 분석
• 기업 히트맵 분석
• 전략 매핑
• 기업 프로파일
  • Merck & Co., Inc.
  • Shanghai Dahua Pharmaceutical Co., Ltd.
  • Bayer AG
  • Baxter
  • BD
  • Gerresheimer AG
  • Pfizer, Inc.
  • Novartis AG
  • SCHOTT
  • Lilly

JHS

영문 목차

영문목차

Subdermal Contraceptive Implants Market Growth & Trends:

The global subdermal contraceptive implants market size is estimated to reach USD 1.74 billion by 2030, registering to grow at a CAGR of 7.61% from 2025 to 2030 according to a new report by Grand View Research, Inc. Introduction of several modern contraceptives in the market, growing awareness about various birth control methods, and high per capita income are some of the key factors driving the market for subdermal implants for birth control.

According to the Guttmacher Institute, in 2014, approximately 20 million women needed publicly funded contraceptive services. According to CDC, in 2017, nearly 46.9 million women in the U.S. were using at least one method of contraception. Subdermal implant is a long-term birth control option for women. Subdermal implants for contraception are in the form of polymer capsules or rods placed under the skin. The progestational hormone is released at a slow and stable rate, providing effective contraception for 1-5 years.

Publicly funded family planning services help women avoid or plan pregnancies. In 2012, the South Carolina Department of Health and Human Services (SCDHHS) revised the cost associated with Medicaid payment policy for immediate postpartum insertion of Long-Acting Reversible Contraception (LARC). Under this new reimbursement policy, providers are allowed to bill for the insertion procedure and the cost of an IUD or an implant, in addition to the Diagnosis Related Group (DRG) by using J-codes with a family planning modifier.

Implants are the most widely used contraceptive methods by women in sub-Saharan Africa owing to public-private partnerships between manufacturers, donors, governments, and international agencies, which helps lower commodity cost and increase product availability. Contraceptive usage has increased in South Africa, Malawi, and Rwanda. According to PLOS.org, in Malawi, the use of the Long-acting Reversible Contraception (LARC) method reached 10.21% in urban areas in 2016 and 9.66% in rural areas. In 2012, an initiative called Family Planning 2020 (FP2020) was launched to give 120 million women access to modern contraceptive methods by 2020.

Subdermal Contraceptive Implants Market Report Highlights:

• Etonogestrel implants dominated the market and accounted for a share of 64.73% in 2024. The driving factors are rising unintended pregnancies and unsafe abortions.
• Hospital dominated the market and accounted for a share of 54.37% in 2024. Hospitals provide a comprehensive environment for patients, offering a wide range of services including tests, consultations, and procedures, which drive segment growth.
• North America subdermal contraceptive implants market dominated the market with a market share of 64.91% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Secondary Sources
  • 1.4.2. List of Primary Sources
  • 1.4.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Distribution Channel Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Subdermal Contraceptive Implants Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Awareness of family planning
    • 3.2.1.2. Demand for Long-Acting Reversible Contraceptives (LARCs)
    • 3.2.1.3. Technological advancements and product improvements
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Side effects and health concerns
  • 3.2.3. Industry Challenges and Opportunity Analysis
• 3.3. Subdermal Contraceptive Implants Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Subdermal Contraceptive Implants Market: Product Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Subdermal Contraceptive Implants Market: By Product, 2018 to 2030
  • 4.4.1. Etonogestrel Implant
    • 4.4.1.1. Etonogestrel implant market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Levonorgestrel Implant
    • 4.4.2.1. Levonorgestrel implant market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Subdermal Contraceptive Implants Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Distribution Channel Market Share Analysis, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Subdermal Contraceptive Implants Market: By Distribution Channel, 2018 to 2030
  • 5.4.1. Hospital
    • 5.4.1.1. Hospital market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Gynecology Clinics
    • 5.4.2.1. Gynecology clinics market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Community Health Care Centers
    • 5.4.3.1. Community health care centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Subdermal Contraceptive Implants Market: Regional Estimates & Trend Analysis by Region, Product

• 6.1. Definition and Scope
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Subdermal Contraceptive Implants Market Share, By Region, 2024 & 2030 (USD Million)
• 6.4. North America
  • 6.4.1. North America Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. U.S. Key Country Dynamics
    • 6.4.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Canada Key Country Dynamics
    • 6.4.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Mexico Key Country Dynamics
    • 6.4.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. UK Key Country Dynamics
    • 6.5.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. U.K. Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Germany Key Country Dynamics
    • 6.5.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. France Key Country Dynamics
    • 6.5.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Italy Key Country Dynamics
    • 6.5.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Spain Key Country Dynamics
    • 6.5.6.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Denmark Spain Key Country Dynamics
    • 6.5.7.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Sweden Key Country Dynamics
    • 6.5.8.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Sweden Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Norway Key Country Dynamics
    • 6.5.9.2. Regulatory Landscape/Reimbursement Scenario
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Norway Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. China Key Country Dynamics
    • 6.6.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. China Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Japan
    • 6.6.3.1. Japan Key Country Dynamics
    • 6.6.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. Japan Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. India Key Country Dynamics
    • 6.6.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. South Korea Key Country Dynamics
    • 6.6.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Australia Key Country Dynamics
    • 6.6.6.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Thailand Key Country Dynamics
    • 6.6.7.2. Regulatory Landscape/Reimbursement Scenario
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Brazil Key Country Dynamics
    • 6.7.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Argentina Key Country Dynamics
    • 6.7.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa (MEA)
  • 6.8.1. Middle East and Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. South Africa Key Country Dynamics
    • 6.8.2.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Saudi Arabia Key Country Dynamics
    • 6.8.3.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. UAE Key Country Dynamics
    • 6.8.4.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Kuwait Key Country Dynamics
    • 6.8.5.2. Regulatory Landscape/Reimbursement Scenario
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Subdermal Contraceptive Implants Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Market Share Analysis
• 7.4. Company Heat Map Analysis
• 7.5. Strategy Mapping
• 7.6. Company Profiles
  • 7.6.1. Merck & Co., Inc.
    • 7.6.1.1. Participant's Overview
    • 7.6.1.2. Financial Performance
    • 7.6.1.3. Product Benchmarking
    • 7.6.1.4. Recent Developments
  • 7.6.2. Shanghai Dahua Pharmaceutical Co., Ltd.
    • 7.6.2.1. Participant's Overview
    • 7.6.2.2. Financial Performance
    • 7.6.2.3. Product Benchmarking
    • 7.6.2.4. Recent Developments
  • 7.6.3. Bayer AG
    • 7.6.3.1. Participant's Overview
    • 7.6.3.2. Financial Performance
    • 7.6.3.3. Product Benchmarking
    • 7.6.3.4. Recent Developments
  • 7.6.4. Baxter
    • 7.6.4.1. Participant's Overview
    • 7.6.4.2. Financial Performance
    • 7.6.4.3. Product Benchmarking
    • 7.6.4.4. Recent Developments
  • 7.6.5. BD
    • 7.6.5.1. Participant's Overview
    • 7.6.5.2. Financial Performance
    • 7.6.5.3. Product Benchmarking
    • 7.6.5.4. Recent Developments
  • 7.6.6. Gerresheimer AG
    • 7.6.6.1. Participant's Overview
    • 7.6.6.2. Financial Performance
    • 7.6.6.3. Product Benchmarking
    • 7.6.6.4. Recent Developments
  • 7.6.7. Pfizer, Inc.
    • 7.6.7.1. Participant's Overview
    • 7.6.7.2. Financial Performance
    • 7.6.7.3. Product Benchmarking
    • 7.6.7.4. Recent Developments
  • 7.6.8. Novartis AG
    • 7.6.8.1. Participant's Overview
    • 7.6.8.2. Financial Performance
    • 7.6.8.3. Product Benchmarking
    • 7.6.8.4. Recent Developments
  • 7.6.9. SCHOTT
    • 7.6.9.1. Participant's Overview
    • 7.6.9.2. Financial Performance
    • 7.6.9.3. Product Benchmarking
    • 7.6.9.4. Recent Developments
  • 7.6.10. Lilly
    • 7.6.10.1. Participant's Overview
    • 7.6.10.2. Financial Performance
    • 7.6.10.3. Product Benchmarking
    • 7.6.10.4. Recent Developments

관련자료